EKF Diagnostics Holdings Plc (EKF) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.068x

Based on the latest financial reports, EKF Diagnostics Holdings Plc (EKF) has a cash flow conversion efficiency ratio of 0.068x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX4.92 Million ≈ $598.62 USD) by net assets (GBX72.88 Million ≈ $8.87K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

EKF Diagnostics Holdings Plc - Cash Flow Conversion Efficiency Trend (2001–2024)

This chart illustrates how EKF Diagnostics Holdings Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read EKF Diagnostics Holdings Plc total liabilities for a breakdown of total debt and financial obligations.

EKF Diagnostics Holdings Plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of EKF Diagnostics Holdings Plc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Focusrite Plc
LSE:TUNE
0.145x
BlockMint Technologies Inc
V:BKMT
-0.024x
Nusantara Inti Corpora Tbk
JK:UNIT
-0.084x
Wang & Lee Group, Inc. Ordinary Shares
NASDAQ:WLGS
0.051x
Arcandor AG
DU:ARO
N/A
Antarctica Limited
NSE:ANTGRAPHIC
-0.337x
Pharos Energy plc
LSE:PHAR
0.058x
elexxion AG
XETRA:E8X
-708202.000x

Annual Cash Flow Conversion Efficiency for EKF Diagnostics Holdings Plc (2001–2024)

The table below shows the annual cash flow conversion efficiency of EKF Diagnostics Holdings Plc from 2001 to 2024. For the full company profile with market capitalisation and key ratios, see EKF stock market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 GBX73.21 Million
≈ $8.91K
GBX13.66 Million
≈ $1.66K
0.187x +101.62%
2023-12-31 GBX68.22 Million
≈ $8.30K
GBX6.31 Million
≈ $767.87
0.093x -28.84%
2022-12-31 GBX74.52 Million
≈ $9.07K
GBX9.69 Million
≈ $1.18K
0.130x +20.30%
2021-12-31 GBX94.74 Million
≈ $11.53K
GBX10.24 Million
≈ $1.25K
0.108x -38.80%
2020-12-31 GBX78.20 Million
≈ $9.51K
GBX13.81 Million
≈ $1.68K
0.177x +146.43%
2019-12-31 GBX71.17 Million
≈ $8.66K
GBX5.10 Million
≈ $620.52
0.072x -44.98%
2018-12-31 GBX63.90 Million
≈ $7.78K
GBX8.32 Million
≈ $1.01K
0.130x -12.96%
2017-12-31 GBX60.50 Million
≈ $7.36K
GBX9.05 Million
≈ $1.10K
0.150x +2.02%
2016-12-31 GBX60.97 Million
≈ $7.42K
GBX8.94 Million
≈ $1.09K
0.147x +260.04%
2015-12-31 GBX46.75 Million
≈ $5.69K
GBX-4.29 Million
≈ $-521.36
-0.092x -68.80%
2014-12-31 GBX87.38 Million
≈ $10.63K
GBX-4.74 Million
≈ $-577.21
-0.054x -210.70%
2013-12-31 GBX40.92 Million
≈ $4.98K
GBX2.01 Million
≈ $244.19
0.049x +20.93%
2012-12-31 GBX39.43 Million
≈ $4.80K
GBX1.60 Million
≈ $194.55
0.041x +288.32%
2011-12-31 GBX37.43 Million
≈ $4.55K
GBX-806.00K
≈ $-98.07
-0.022x +64.04%
2010-12-31 GBX23.53 Million
≈ $2.86K
GBX-1.41 Million
≈ $-171.43
-0.060x +50.22%
2009-12-31 GBX5.62 Million
≈ $683.79
GBX-676.00K
≈ $-82.25
-0.120x +5.74%
2008-12-31 GBX5.07 Million
≈ $616.87
GBX-647.00K
≈ $-78.72
-0.128x -210.05%
2007-12-31 GBX4.98 Million
≈ $605.44
GBX577.00K
≈ $70.20
0.116x +160.35%
2006-12-31 GBX4.30 Million
≈ $523.06
GBX-826.00K
≈ $-100.50
-0.192x -3668.00%
2005-12-31 GBX3.71 Million
≈ $451.89
GBX20.00K
≈ $2.43
0.005x +101.97%
2004-12-31 GBX3.12 Million
≈ $379.01
GBX-852.00K
≈ $-103.66
-0.274x -2390.00%
2003-12-31 GBX2.46 Million
≈ $299.07
GBX-27.00K
≈ $-3.29
-0.011x -498.46%
2002-12-31 GBX2.90 Million
≈ $353.09
GBX8.00K
≈ $0.97
0.003x -99.58%
2001-12-31 GBX214.00K
≈ $26.04
GBX142.00K
≈ $17.28
0.664x --

About EKF Diagnostics Holdings Plc

LSE:EKF UK Medical Devices
Market Cap
$1.39 Million
GBX11.46 Billion GBX
Market Cap Rank
#29998 Global
#743 in UK
Share Price
GBX26.55
Change (1 day)
-0.56%
52-Week Range
GBX19.80 - GBX31.90
All Time High
GBX78.21
About

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that pr… Read more